EMA to Review Berotralstat as Preventive Treatment for HAE Swelling Attacks
The European Medicines Agency has validated BioCryst Pharmaceuticals‘ application requesting the approval of berotralstat as a once-daily oral treatment to prevent swelling attacks in people with hereditary angioedema (HAE). The Committee for Medicinal Products for Human Use, an advisory committee for the European Union’s regulatory agency,…